Work

Exploring innovative strategies to enhance osteoporotic lumbar fusion: Efficacy of local delivery of prostaglandin EP4 receptor agonist KMN-159 and zoledronic acid in a rat model

Year: 2025

Type: conference-paper

Abstract: Objectives and questions: Spinal fusion in patients with osteoporosis is challenging [ref:1]. rhBMP-2 is the only FDA-approved osteoinductive agent but has high costs and side effects [ref:2]. KMN-159, a novel prostaglandin EP4 receptor agonist, promotes spinal fusion in healthy [for full text, please go to the a.m. URL]

Source: German Medical Science (German Research Foundation)

DOI: 10.3205/25dkou275

Authors: Tian, Xinggui, Schroeter, Paul, Vater, Corina, Pei, Xuan, Schaser, Klaus-Dieter, Disch, Alexander, Zwingenberger, Stefan

Institution: University Hospital Carl Gustav Carus

Language: English

Topic: Spine and Intervertebral Disc Pathology

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W7103173297

FWCI:

Cites:

Cited by:

Related to: